Long-term remission & control of CVD risk factors can reduce the risk of atherosclerosis in lupus; triple APL positivity raises the risk of CVD, study finds.
Systemic Lupus Erythematosus Resource Center
Watch this space for our coverage of systemic lupus erythematosus (SLE) sessions at ACR Convergence 2020, beginning with a report on the State of the Art: Lupus—the Future Is Now session, moderated by Saira Sheikh, MD. Plus, explore our collection of research reviews, case reports and clinical articles on advances in the diagnosis and management of SLE.
VIEW
New Patient- & Provider-Focused Resources Focus on Improving Lupus Care
With resources and programs running online and on the ground in 47 states, COIN’s projects are having a massive impact on the field of rheumatology.
Rethinking Lupus Nephritis: Are Current Approaches & Guidelines off Target?
A rheumatologist & lupus expert reviews lupus nephritis treatment, questioning proteinuria cutoffs & ACR guidelines, advocating for newer therapies & end-of-treatment biopsies.
10 Things to Know about Lupus
SLE treatment is rapidly evolving as new therapies are developed & approved. Here are 10 key insights for clinicians.
3 AC&R Study Summaries: Avoidable RA Hospitalizations, Psoriasis to Psoriatic Arthritis Transition, & Neighborhood Conditions in Childhood Lupus
New studies reveal predictors for avoidable RA hospitalizations, PsA transition in psoriasis & the impact of neighborhood on childhood lupus.
B Original: B Cells, Non-Invasive Biomarkers & More
Experts discussed how aspects of the immune system other than B cells play a role in lupus, including mitochondria in red blood cells, proteins present in urine and more.
Highlights from the European Congress of Internal Medicine
An overview of highlights from the 2025 ECIM meeting, including research on treatment options for systemic sclerosis, the management of PMR & autoimmune testing.
Rheuminations: Can We Now Control the Wolf?
Lupus has always had a reputation for being a wild, unrestrained and enigmatic entity. In fact, the very name lupus comes from the Latin word for wolf, a gift from our Roman predecessors who saw a resemblance between lupus rashes and a wolf’s bite. Given the limitations of immunology back then, it is an incredibly…
FDA Approvals: Lupus Nephritis
Lupus nephritis is one of the leading causes of mortality for patients with systemic lupus erythematosus (SLE), and patients with both SLE and end-stage renal disease have standardized mortality ratios more than 60 times that of patients with SLE with normal kidney function.1 The good news: Rheumatologists now have not one, but two approved options…
Trials Find Potential Treatments for SLE, Lupus Nephritis
In summer 2024, two phase 3 studies were released with promising findings for the treatment of patients with systemic lupus erythematosus (SLE) and those with lupus nephritis. SLE Disease Activity Dapirolizumab pegol is a novel, investigational, Fc-free anti-CD40L agent for people living with moderate to severe SLE.1 The randomized, double-blind, parallel-group PHOENYCS GO trial (N=321)…
- 1
- 2
- 3
- …
- 45
- Next Page »